Literature DB >> 26268688

An opportunity for further control of hepatitis B in China?

Claudia Vellozzi1, Francisco Averhoff2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26268688     DOI： 10.1016/S1473-3099(15)00245-5

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

1.  Prevalence and Determinants of Cryptosporidium Infection in an Underdeveloped Rural Region of Southwestern China.

Authors:  Ya Yang; Yibiao Zhou; Wanting Cheng; Xiang Pan; Penglei Xiao; Yan Shi; Jianchuan Gao; Xiuxia Song; Yue Chen; Qingwu Jiang
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

2.  Peripheral Blood Microbiome Analysis via Noninvasive Prenatal Testing Reveals the Complexity of Circulating Microbial Cell-Free DNA.

Authors:  Xunliang Tong; Xiaowei Yu; Yang Du; Fei Su; Ye Liu; Hexin Li; Yunshan Liu; Kai Mu; Qingsong Liu; Hui Li; Jiansheng Zhu; Hongtao Xu; Fei Xiao; Yanming Li
Journal:  Microbiol Spectr       Date:  2022-05-24

3.  Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis.

Authors:  S Banerjee; P Gunda; R F Drake; K Hamed
Journal:  Springerplus       Date:  2016-10-05

4.  Spatio-Temporal Epidemiology of Viral Hepatitis in China (2003-2015): Implications for Prevention and Control Policies.

Authors:  Bin Zhu; Jinlin Liu; Yang Fu; Bo Zhang; Ying Mao
Journal:  Int J Environ Res Public Health       Date:  2018-04-02       Impact factor: 3.390
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.